Sugi Predict

Sugi Predict / Compounds / SCHEMBL78071

SCHEMBL78071

SCHEMBL78071

CC1(O)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HPGD P15428 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ GPR119 Q8TDV5 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ POLB P06746 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524618 0.93 HPGD (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL2218646 0.89 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL25286793 0.89 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2RECQL
Hydrochloric Acid SCHEMBL3945987 0.89 USP2 (0.45) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL3436829 0.86 USP2 (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL21142647 0.86 HPGD (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL21145918 0.86 HPGD (0.56) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL2157153 0.85 HPGD (0.49) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL24107089 0.85 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL2673968 0.83 NR1H2 (0.44) USP2SMN1; SMN2HPGDEPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874121-A Method for preparing material containing monothiocarbonate group and product 浙江大学 2022-08-09 — — CN claimed
US-12630562-B2 Piperidylurea compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2026-05-19 — — US disclosed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 — — US disclosed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 — — EP disclosed
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-02-12 — — US disclosed
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN BIOMEA FUSION INC (US) 2025-11-20 — — US disclosed
EP-4642778-A1 LSD1 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-11-05 — — EP disclosed
EP-4631940-A1 COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF Betta Pharmaceuticals Co., Ltd. (CN) 2025-10-15 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 — — WO disclosed
WO-2006038923-A2 ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-04-13 — — WO disclosed
WO-2006034338-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE XENON PHARMACEUTICALS INC. (CA) 2006-03-30 — — WO disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C USP2 2094/4885SMN1; SMN2 218/4885HPGD 4099/4885
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1839/4885SMN1; SMN2 1440/4885HPGD 2505/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1819/4885SMN1; SMN2 1656/4885HPGD 2709/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 USP2 1839/4885SMN1; SMN2 1440/4885HPGD 2505/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885HPGD 2049/4885
US-12630562-B2 Piperidylurea compounds and methods of use thereof CLIC1, HCCS, CNR1 USP2 2466/4885SMN1; SMN2 1154/4885HPGD 3748/4885
US-20250353854-A1 FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN MEN1, MLLT1, MSI2 USP2 3835/4885SMN1; SMN2 2354/4885HPGD 2181/4885
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF CBR1, CLIC1, RER1 USP2 2383/4885SMN1; SMN2 1375/4885HPGD 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.